The week in pharma: action, reaction and insight – week to January 21, 2022

23 January 2022

By Barbara Obstoj-Cardwell. Editor

Last week’s notable announcements included Swiss pharma giant Roche saying it has regenerated a previously dropped compound, tominersen - licensed from Ionis Pharmaceuticals, to develop it for Huntington’s disease. Belgium’s biggest pharma firm UCB announced a takeover bid worth up to $1.9 billion for USA-based Zogenix and its epilepsy drug Fintepla. Biotech firm Altos Labs came out of stealth with some $3 billion in financing and luring GlaxoSmithKline’s research chief Hal Barron to be its chief executive, along with several notables to its team. On the research front, Alnylam Pharmaceuticals presented new data supporting its investigational drug vutrisiran in transthyretin amyloidosis.

Roche and Ionis bring tominersen back from the dead

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK